The Akt-inhibitor GDC-0068 displayed antitumor activity towards breast cancer metastatic cells with activating mutations in the PI3K pathway in vitro and inhibited the growth of PIK3CA-mutant tumors breast cancer brain metastases in vivo108. Here, AKT1 is linked to breast carcinoma.